title: Use of cyclosporine pharmacokinetic profiles in an antibody induction protocol reduces early acute rejection rates in recipients of primary cadaveric renal allografts.
authors.affiliation: Department of Urology, Loyola University Medical Center, Maywood, Illinois 60153, USA.
authors.forename: R
authors.initials: R
authors.lastname: Lewis
authors.forename: J
authors.initials: J
authors.lastname: Coutee
authors.forename: D
authors.initials: D
authors.lastname: Steinmuller
authors.forename: D
authors.initials: D
authors.lastname: Hatch
authors.forename: S
authors.initials: S
authors.lastname: Manion
authors.forename: R
authors.initials: R
authors.lastname: Agrawal
authors.forename: D
authors.initials: D
authors.lastname: Moel
authors.forename: R
authors.initials: R
authors.lastname: Flanigan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000917:Antibody Formation; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002102:Cadaver; D002648:Child; D015331:Cohort Studies; D016572:Cyclosporine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005006:Ethnicity; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D013997:Time Factors; D014019:Tissue Donors
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine